Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 How serendipity sent this oncologist in search of a cure for... August 12, 2022 Surprise! Financial Assistance To Help With Your Medical Bills May Be... December 20, 2023 New Research Looks for More Effective Breast Cancer Treatments for Black... January 12, 2021 Load more HOT NEWS Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... EMA Recommends Extension of Therapeutic Indications for Rucaparib Meet the teams tackling 5 challenges in children’s and young people’s... Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?
